Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Aust J Gen Pract ; 49(1-2): 44-47, 2020.
Article in English | MEDLINE | ID: mdl-32008263

ABSTRACT

BACKGROUND: Granulomatous lobular mastitis (GM) is a rare chronic benign inflammatory breast condition. It can present a diagnostic challenge and mimic inflammatory carcinoma. It causes significant morbidity for affected patients. OBJECTIVE: The aim of this article is to provide a clinical update and case study for general practitioners, who are usually the first to see the patient. DISCUSSION: GM is usually idiopathic. The condition presents with a large painful lump with erythema. There is often ulceration, abscess and sinus formation. Triple assessment is needed to confirm diagnosis. GM may last for 12 months or more before healing occurs. Options for management are conservative/supportive care, oral prednisone or methotrexate, or surgical excision. At present, there is no universally accepted management strategy for GM; therefore, treatment will depend on the symptoms, extent of disease and patient preferences. Supporting the patient in coping with the long-term nature of GM and the chronic discharging lesions is essential.


Subject(s)
Granulomatous Mastitis/diagnosis , Adult , Diagnosis, Differential , Female , Granulomatous Mastitis/physiopathology , Humans
2.
Aust J Gen Pract ; 48(9): 604-608, 2019 09.
Article in English | MEDLINE | ID: mdl-31476829

ABSTRACT

BACKGROUND: Breast cancer affects one in eight Australian women. While surgery, chemotherapy, radiotherapy and endocrine therapy are still the main treatments, there have been changes in the sequencing of treatment and advances in each therapy. The general practitioner (GP) is involved at each stage of the patient's journey. OBJECTIVE: This article discusses the current approach to the management of early breast cancer. It focuses on changes in recent years and discusses the role of the GP in supporting women in their decision-making and treatment. DISCUSSION: Key changes include the increasing use of neoadjuvant chemotherapy, the development of advanced oncoplastic surgery and breast reconstruction techniques, the use of gene expression profiling and the recommendation for extended adjuvant endocrine therapy for up to 10 years.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Breast Neoplasms/therapy , Mammaplasty , Mastectomy , Neoadjuvant Therapy , Aromatase Inhibitors/therapeutic use , Axilla , Breast Cancer Lymphedema , Breast Neoplasms/pathology , Chemotherapy, Adjuvant , Female , General Practitioners , Humans , Lymph Node Excision , Mastectomy, Segmental , Neoplasm Staging , Physician's Role , Radiotherapy, Adjuvant , Tamoxifen/therapeutic use , Trastuzumab/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...